Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Stein

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
Genes, Chromosomes & Cancer|December 7, 2013
Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practiceEike Burandt, Melanie Schreiber, Alexander Stein, et al.
Oncology Research and Treatment|May 29, 2026
Safety and preliminary activity of neoadjuvant trastuzumab deruxtecan (T-DXd) plus 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma: Results from the safety run-in cohort of the phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trialGertraud Stocker, Jack Chater, Thomas J Ettrich, et al.
Acta Oncologica (Stockholm, Sweden)|October 14, 2014
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort studyAlexander Stein, Volker Petersen, Mathias Schulze, et al.
BMC Cancer|February 12, 2016
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation studyAlexander Stein, Julia Quidde, Jan Klaus Schröder, et al.
NPJ Precision Oncology|August 5, 2025
Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancerLisa Paschold, Christoph Schultheiss, Paul Schmidt-Barbo, et al.
BMC Cancer|August 1, 2015
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialAlexander Stein, Dirk Arnold, John Bridgewater, et al.
Clinical Rehabilitation|March 9, 2021
Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors - the randomized phase II Motivate AYA - MAYA trialJannike Salchow, Barbara Koch, Julia Mann, et al.
BMC Cancer|August 1, 2024
Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trialConstantin Schmidt, Antonia Zapf, Ann-Kathrin Ozga, et al.
Cancer Immunology, Immunotherapy : CII|August 29, 2014
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junctionMarie-Cristine Kuehnle, Sebastian Attig, Cedrik M Britten, et al.
British Journal of Cancer|November 25, 2020
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUPGunnar Folprecht, Karolin Trautmann, Alexander Stein, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Genes, Chromosomes & Cancer|December 7, 2013
Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practiceEike Burandt, Melanie Schreiber, Alexander Stein, et al.
Oncology Research and Treatment|May 29, 2026
Safety and preliminary activity of neoadjuvant trastuzumab deruxtecan (T-DXd) plus 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma: Results from the safety run-in cohort of the phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trialGertraud Stocker, Jack Chater, Thomas J Ettrich, et al.
Acta Oncologica (Stockholm, Sweden)|October 14, 2014
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort studyAlexander Stein, Volker Petersen, Mathias Schulze, et al.
BMC Cancer|February 12, 2016
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation studyAlexander Stein, Julia Quidde, Jan Klaus Schröder, et al.
NPJ Precision Oncology|August 5, 2025
Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancerLisa Paschold, Christoph Schultheiss, Paul Schmidt-Barbo, et al.
BMC Cancer|August 1, 2015
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialAlexander Stein, Dirk Arnold, John Bridgewater, et al.
Clinical Rehabilitation|March 9, 2021
Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors - the randomized phase II Motivate AYA - MAYA trialJannike Salchow, Barbara Koch, Julia Mann, et al.
BMC Cancer|August 1, 2024
Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trialConstantin Schmidt, Antonia Zapf, Ann-Kathrin Ozga, et al.
Cancer Immunology, Immunotherapy : CII|August 29, 2014
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junctionMarie-Cristine Kuehnle, Sebastian Attig, Cedrik M Britten, et al.
British Journal of Cancer|November 25, 2020
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUPGunnar Folprecht, Karolin Trautmann, Alexander Stein, et al.
Pageof 15